THE INVENTION IS BASED ON THE DISCOVERY OF TWO MODIFIED FORMS OF FACTOR 4 OF THE HUMAN PLATELETS, HERE CALLED MPF-4 AND CPF-4, WHICH WERE ISOLATED FROM A SERUM-FREE LEUKOCYTED MEDIA OF LEUKOCYTES WITH PERIFER BLOOD LIPOPOLYSACCHARIDES. THE DETERMINATION OF THE AMINO ACID SEQUENCE HAS REVEALED THAT THE MPF-4 SHARES HOMOLOGIES WITH THE FACTOR 4 OF THE PLATELETS BEGINNING AT THE 17 N TERMINAL WASTE. THE CPF-4 CONSISTS OF MPF-4 DISULFIDE ATTACHED TO THE 16 WASTE N TERMINAL N OF FACTOR 4 OF THE PLATELETS. BOTH MPF-4 AND CPF-4 ARE POWERFUL INHIBITORS IN THE PROLIFERATION OF ENDOTHELIAL CELLS, BETWEEN 10 AND 100 TIMES MORE POWERFUL THAN NATIVE OR THE RECOMBINANT FACTOR 4 OF THE PLATELETS, MAKING THEM USEFUL IN THE TREATMENT OF DISEASES.
展开▼
